Reported 2 days ago
Lantheus Holdings, Inc. (NASDAQ:LNTH), a company specializing in radiopharmaceuticals and diagnostic imaging, has completed the acquisition of Life Molecular Imaging Limited for $350 million to boost its capabilities in Alzheimer's diagnostics. This move comes despite a recent dip in the company's share performance, which saw declines of 10.98% weekly and 8.65% monthly. Analysts maintain a positive outlook with a Buy rating, expecting an 8.36% growth in earnings per share over the next five years, positioning Lantheus as a potentially strong long-term investment.
Source: YAHOO